查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018960

肥胖症治療市場：2026-2032年全球市場預測（依治療方法、藥物類別、給藥途徑、病患年齡層、分銷管道和最終用戶分類）

Obesity Treatment Market by Treatment Type, Drug Class, Route of Administration, Patient Age Group, Distribution Channel, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年肥胖症治療市場價值 166.9 億美元，預計到 2026 年將成長至 180.2 億美元，複合年成長率為 8.45%，到 2032 年將達到 294.6 億美元。

主要市場統計數據
基準年 2025 166.9億美元
預計年份：2026年 180.2億美元
預測年份 2032 294.6億美元
複合年成長率 (%) 8.45%

明確了融合臨床創新、系統性挑戰和策略重點的方向，這些正在重塑肥胖症治療的提供方式，並為相關人員。

肥胖症治療處於臨床創新、不斷變化的患者期​​望和不斷演進的醫療政策的交匯點，這需要細緻入微的策略思考。藥物治療，特別是腸促胰素療法的進步，透過提供新的​​非手術選擇，重塑了治療模式，改變了治療路徑、患者轉診模式以及支付方的參與方式。同時，外科手術介入也在不斷發展，採用微創技術和精細的手術全期護理，在臨床病情嚴重且合併症較多的情況下，仍然發揮著持續的解剖學干預作用。

臨床範式、交付模式和支付方期望的演變正在推動肥胖症治療從孤立的干涉措施向縱向的、全面的護理模式進行系統性轉變。

肥胖症治療領域正經歷一場變革，其驅動力來自藥物治療的突破性進展、外科治療的改進以及數位治療方法的日趨成熟。在藥物治療方面，利用代謝和食慾調節路徑的治療方法已展現出顯著的臨床減重效果，並伴隨廣泛的心血管代謝獲益，這促使臨床醫生和支付方重新評估治療方案和順序。這種轉變正在加速整合內分泌學、基層醫療、行為醫學和營養服務的多學科診療模式的發展，從而增加持續患者管理的接觸點。

預計 2025 年的貿易政策調整將對營運、定價和准入產生多方面的影響，因此，採取積極主動的參與策略來加強供應鏈的韌性和償還能力至關重要。

2025年若美國推出新的關稅或調整貿易政策，將帶來一系列累積影響，整個肥胖症治療生態系統的相關人員必須評估並應對這些影響。對進口藥品活性成分、給藥裝置或特殊醫療設備徵收關稅，將增加依賴全球供應鏈的製造商的投入成本。這些成本壓力將波及整個分銷管道，並可能影響藥品標價、回扣策略以及與支付方和醫療服務提供者的談判動態。價格上漲的轉嫁程度將取決於合約結構和治療領域的競爭強度。

從多維細分觀點，將治療方法、藥理分類、給藥途徑、患者群體、分銷管道和醫療保健環境與策略挑戰聯繫起來。

細分市場分析揭示了治療方法、藥理機制、給藥途徑、患者人口統計特徵、分銷管道和終端用戶環境之間複雜的相互作用。這些因素各自對臨床實務和商業策略產生獨特的影響。根據治療類型，該領域包括藥物治療和外科手術。藥物治療又可細分為非處方藥和處方藥，而外科手術則包括減重手術、胃繞道手術和腹腔鏡手術。這些區分至關重要，因為每種途徑都涉及不同的臨床決策點、監管要求和患者教育需求，這些因素決定了從初次諮詢到長期追蹤的患者治療過程中涉及的相關人員類型。

美洲、歐洲、中東和非洲以及亞太地區的監管、報銷和文化趨勢各不相同，因此需要針對每個地區制定量身定做的准入和證據策略。

區域趨勢差異顯著，因此在監管溝通、准入策略和夥伴關係建設方面需要採取差異化的方法。在美洲，北美監管流程依託於完善的臨床試驗基礎設施和更成熟的支付方框架，能夠快速引進週期療效顯著且報銷機制與療效相符的治療方法。該地區的醫療保健系統也面臨著巨大的未滿足需求和人口多樣性，這為整合式醫療模式和基於價值的合約創造了機遇，從而將報銷與永續的臨床獲益掛鉤。

能夠將差異化的臨床結果證據、整合的護理夥伴關係以及適應性強的商業和供應鏈能力結合起來的組織將獲得競爭優勢。

如今，競爭格局日益取決於企業能否展現差異化的臨床療效、最佳化服務交付和支持，並以令人信服的衛生經濟學證據贏得支付方的認可。領先的生物製藥研發公司正投資於療效研究和患者支持項目，以解決用藥依從性、治療連續性和長期安全性監測等問題。同時，醫療設備和手術創新者正致力於改善手術全期照護路徑，並強化促進復健的方案，以減少併發症和降低治療總成本。製藥公司與專科診所和數位醫療服務提供者之間的夥伴關係正在興起，成為將行為介入、遠端監測和用藥依從性支援整合到商業服務中的一種有效途徑，從而提升支付方和病患的價值。

為了確保獲得服務並加快推廣，領導者需要加強其價值鏈，建立基於價值的證據，並透過實踐和協作努力來擴展綜合患者照護服務模式。

產業領導者應推動一系列協作舉措，協調臨床證據的取得、供應鏈韌性以及與支付方的合作，以維持醫療服務的可及性並促進創新。首先，應實現採購管道多元化，投資本地製造和策略供應商合作，以減輕貿易政策中斷的影響，並降低活性成分和一次性醫療設備等關鍵投入品的交貨前置作業時間風險。除了供應側措施外，還應最佳化庫存，並在合約中加入條款，以便在地緣政治不確定性加劇時期保持靈活性。

透過採用多層次的調查方法，結合對關鍵相關人員的訪談、有針對性的二手資料和嚴格的檢驗，我們確保獲得可操作且引人注目的見解。

本研究途徑結合了多層次的調查方法，旨在從多元可靠的資訊來源獲取資訊並進行檢驗。主要研究內容包括對臨床醫生、支付方、採購經理和患者權益倡導組織代表進行結構化訪談，以獲取關於臨床決策、報銷限制和就醫障礙的第一手觀點。除訪談外，專家諮詢小組還會進行主題檢驗和情境測試、策略性假設壓力測試，並識別新出現的營運風險。

一份簡明扼要、全面全面的報告，強調了透過整合臨床證據、營運彈性和支付方合作來改善治療效果和維持醫療服務可近性的策略必要性。

肥胖症治療生態系統正處於轉折點，臨床創新、供應鏈現狀和支付方期望相互交織，重新定義了治療路徑。積極將循證醫學成果與切實可行的准入策略和穩健的運營計劃相結合的相關人員，將在改善患者預後的同時，獲得更大的價值。藥物治療進展與手術治療的相互作用凸顯了採用綜合性跨學科方法的必要性，這種方法需要考慮患者的異質性和長期管理需求。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依治療方法分類的肥胖症治療市場

  • 藥物治療
    • 非處方藥
    • 處方藥
  • 手術治療
    • 減重手術
    • 胃繞道手術
    • 腹腔鏡手術

第9章：肥胖症治療市場：依藥物類別分類

  • 食慾抑制劑
  • GLP-1受體促效劑
  • 脂肪酶抑制劑
  • 代謝加速器

第10章：肥胖症治療市場：依給藥途徑分類

  • 口服
  • 腸外

第11章：依患者年齡層分類的肥胖症治療市場

  • 成人
  • 老年人
  • 兒童

第12章 肥胖症治療市場：依通路分類

  • 實體零售
  • 線上零售

第13章 肥胖症治療市場：依最終使用者分類

  • 醫院和診所
  • 專科診所
  • 減重與健康中心

第14章 肥胖症治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 肥胖症治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 肥胖症治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國肥胖症治療市場

第18章：中國肥胖症治療市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Apollo Endosurgery, Inc.
  • AstraZeneca PLC
  • Atkins Nutritionals, Inc.
  • BTL Aesthetics
  • CH Boehringer Sohn AG & Ko. KG
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc.
  • Herbalife Ltd.
  • Johnson & Johnson Services, Inc.
  • Kellogg Company
  • Medtronic PLC
  • Merck & Co.
  • Novo Nordisk A/S
  • NutriSystem, Inc.
  • Olympus Corporation
  • Pfizer, Inc.
  • ReShape Lifesciences, Inc.
  • Rhythm Pharmaceuticals, Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Viking Therapeutics, Inc.
  • VIVUS LLC
  • Zealand Pharma A/S
Product Code: MRR-EC2E133E32E2

The Obesity Treatment Market was valued at USD 16.69 billion in 2025 and is projected to grow to USD 18.02 billion in 2026, with a CAGR of 8.45%, reaching USD 29.46 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 16.69 billion
Estimated Year [2026] USD 18.02 billion
Forecast Year [2032] USD 29.46 billion
CAGR (%) 8.45%

A clear orientation to the converging clinical innovations, system-level challenges, and strategic priorities that are reshaping obesity treatment delivery and stakeholder opportunity

Obesity treatment sits at the intersection of clinical innovation, shifting patient expectations, and evolving health policy, creating a landscape that demands nuanced strategic thinking. Advances in pharmacotherapy-most notably in incretin-based therapies-have reframed treatment paradigms by offering new non-surgical options that alter care pathways, patient referral patterns, and payer interactions. At the same time, surgical interventions continue to evolve with less invasive techniques and refined perioperative care, maintaining their role where clinical severity and comorbidity profiles necessitate durable anatomical interventions.

Healthcare providers, pharmaceutical developers, device manufacturers, and payers must reconcile these clinical advances with persistent challenges: inconsistent access across demographic groups, fragmented reimbursement frameworks, and pressures on supply chains for active pharmaceutical ingredients and delivery devices. Innovations in digital health, remote monitoring, and patient engagement platforms are beginning to close gaps in follow-up care and behavioral intervention, yet they require integration into existing care ecosystems to deliver measurable outcomes. Consequently, stakeholders who align clinical evidence generation with pragmatic access strategies and cross-disciplinary partnerships will be best positioned to influence both patient outcomes and organizational performance.

This introduction frames the subsequent analysis by emphasizing the interconnected drivers of change-clinical efficacy, delivery modality, regulatory pathways, and commercial strategy-and sets expectations for decision-makers seeking pragmatic, evidence-based guidance. The narrative that follows dissects transformative forces in the field, regulatory and trade headwinds, segmentation-level implications for product and service design, and actionable recommendations to navigate near-term disruption while building long-term resilience.

Evolving clinical paradigms, delivery modalities, and payer expectations are driving a systemic shift from episodic intervention toward longitudinal integrated care models for obesity treatment

The obesity treatment landscape is undergoing transformative shifts driven by breakthroughs in pharmacotherapy, refinements in surgical practice, and the maturation of digital therapeutics. In pharmacology, therapies that harness metabolic and appetite-regulating pathways have demonstrated clinically relevant weight reductions tied to broader cardiometabolic benefits, prompting clinicians and payers to reevaluate lines of therapy and treatment sequencing. This shift is accelerating multidisciplinary care models that integrate endocrinology, primary care, behavioral health, and nutrition services, creating more touchpoints for sustained patient management.

At the same time, procedural innovation in bariatric and minimally invasive surgery has improved perioperative safety and recovery timelines, preserving the role of surgical options for patients with advanced disease or refractory responses to medical therapy. Delivery modalities are also diversifying: oral formulations and parenteral administration coexist, and each route creates distinct adherence, storage, and patient support needs. Parallel to clinical advances, distribution channels are evolving. Retail and specialty clinic models are adapting to omnichannel patient journeys where in-person consultations, telemedicine follow-ups, and e-commerce fulfillment must be coordinated to ensure continuity of care.

Policy and payer landscapes are adapting unevenly, with some payers expanding coverage for pharmacologic therapies contingent on demonstrable outcomes, while others maintain restrictive criteria. This differential access amplifies disparities and incentivizes manufacturers to develop robust real-world evidence and value-based contracting approaches. Overall, the sector is shifting from episodic interventions toward longitudinal management frameworks that blend clinical innovation with systems thinking, emphasizing sustained outcomes, patient experience, and economic value.

Projected trade policy adjustments in 2025 will create compounding operational, pricing, and access implications that necessitate proactive supply chain resilience and reimbursement engagement strategies

The introduction of additional tariffs or trade policy changes in the United States in 2025 introduces a set of cumulative effects that stakeholders across the obesity treatment ecosystem must evaluate and mitigate. Tariffs on imported active pharmaceutical ingredients, delivery devices, or specialized medical equipment would increase input costs for manufacturers that rely on global supply chains. Those cost pressures are likely to cascade through distribution channels, influencing list prices, rebate strategies, and negotiation dynamics with payers and healthcare providers. The magnitude of price transmission will vary depending on contracting structures and the competitive intensity within therapeutic categories.

Beyond immediate cost impacts, tariffs can alter supplier behavior and investment timelines. Suppliers may reshore production, diversify sourcing, or invest in higher inventory buffers to reduce exposure to trade policy volatility. Such strategic moves require capital and time and may lead to short- to medium-term supply inflection points as capacity is reallocated. For parenteral therapies and single-use delivery devices, where sterility and regulatory approvals constrain supplier interchangeability, any disruption can have outsized effects on availability and clinical operations. Facilities that perform bariatric procedures may face increased equipment and implant costs that influence procedural economics and case selection criteria.

Tariff-driven cost increases also have implications for research and development prioritization. Companies may need to reassess pipeline investments or prioritize projects with lower dependency on at-risk imports. At the payer and provider level, increased costs could intensify scrutiny around comparative effectiveness and long-term outcomes, accelerating demand for real-world evidence and health economic analyses. In public health terms, policies that reduce affordability or access could exacerbate existing disparities, disproportionately affecting populations with limited healthcare access or higher baseline prevalence of obesity. Consequently, comprehensive mitigation strategies-including sourcing diversification, collaborative contracting with payers, investment in domestic manufacturing where feasible, and proactive stakeholder communication-are essential to preserve continuity of care and maintain momentum in therapeutic adoption.

A multi-dimensional segmentation perspective connecting treatment modalities, pharmacologic classes, administration routes, patient cohorts, channels, and care settings to strategic imperatives

Segmentation analysis reveals the complex interplay among treatment modalities, pharmacologic mechanisms, administration routes, patient demographics, distribution channels, and end-user settings, each of which carries distinct implications for clinical practice and commercial strategy. Based on treatment type, the landscape includes pharmacotherapy and surgical procedures; pharmacotherapy further divides into over-the-counter drugs and prescription medications, while surgical procedures encompass bariatric surgery, gastric bypass, and laparoscopic surgery. These distinctions matter because each pathway involves different clinical decision points, regulatory requirements, and patient education needs, and they determine the types of stakeholders involved in patient journeys from initial consultation through long-term follow-up.

Based on drug class, therapeutic approaches span appetite suppressants, GLP-1 receptor agonists, lipase inhibitors, and metabolism boosters, each presenting unique efficacy, safety, and monitoring profiles that inform both prescriber behavior and payer criteria. Based on route of administration, the market includes oral and parenteral options; oral therapies offer convenience and potentially broader uptake, while parenteral agents may deliver higher efficacy or different tolerability characteristics and will require administration support and cold-chain logistics. Based on patient age group, stakeholders must address the different clinical needs and adherence challenges of adults, elderly patients, and pediatric populations, paying particular attention to dosing, comorbidity profiles, and long-term follow-up strategies.

Based on distribution channel, treatment access occurs through offline retail and online retail models; offline settings continue to play a critical role for procedural interventions and in-person clinical management, while online channels expand access for certain pharmacologic therapies and ongoing patient support. Based on end-user, services and products are delivered across hospitals and clinics, specialty clinics, and weight loss and wellness centers, each with distinct procurement practices, clinical workflows, and reimbursement environments. Integrating these segmentation lenses reveals where product design, channel strategy, and evidence generation must align to meet clinical needs and payer expectations across diverse patient cohorts and care settings.

Distinct regional regulatory, reimbursement, and cultural dynamics across the Americas, Europe Middle East Africa, and Asia Pacific require tailored access and evidence strategies

Regional dynamics vary significantly and require differentiated approaches to regulatory engagement, access strategy, and partnership development. In the Americas, regulatory pathways in North America leverage robust clinical trial infrastructure and more mature payer frameworks, producing rapid adoption cycles for high-efficacy therapies where reimbursement aligns with demonstrated outcomes. Health systems in the region are also contending with substantial unmet need and demographic heterogeneity, which creates opportunities for integrated care models and value-based contracting that tie reimbursement to sustained clinical benefit.

In Europe, the Middle East & Africa, regulatory regimes present a patchwork of approval timelines and reimbursement criteria that necessitate targeted market entry planning and local evidence generation. Several countries prioritize cost-effectiveness and comparative analyses within health technology assessment frameworks, driving the need for region-specific real-world data and economic models. In many emerging markets across these regions, infrastructure constraints and out-of-pocket payment prevalence affect the feasible adoption pathways for both pharmacologic and surgical interventions.

In the Asia-Pacific region, market heterogeneity includes advanced markets with sophisticated regulatory systems alongside rapidly developing health systems where rising prevalence and growing middle-class demand are increasing access to obesity treatments. Supply chain considerations, local manufacturing capacities, and regional regulatory harmonization efforts influence launch sequencing and commercial investments. Across all regions, cultural perceptions of obesity, provider training, and the availability of multidisciplinary care teams shape adoption curves and long-term treatment paradigms, making localized stakeholder engagement and tailored evidence packages essential for successful program implementation.

Competitive advantage will accrue to organizations that combine differentiated clinical outcomes evidence, integrated care partnerships, and adaptable commercial and supply chain capabilities

Competitive dynamics are increasingly defined by the ability to demonstrate differentiated clinical outcomes, optimize delivery and support services, and engage payers with persuasive health economic evidence. Leading biopharmaceutical developers are investing in outcome studies and patient support programs to address adherence, persistence, and long-term safety monitoring, while device and procedural innovators emphasize improved perioperative pathways and enhanced recovery protocols to reduce complications and total episode costs. Partnerships between drug developers and specialty clinics or digital health providers are emerging as a way to integrate behavioral interventions, remote monitoring, and adherence support into commercial offerings, increasing the perceived value for payers and patients alike.

Strategic capabilities that separate successful organizations from peers include robust real-world evidence generation, flexible manufacturing and supply chain arrangements, and sophisticated payer engagement models that can support value-based reimbursement. Companies that invest in education for clinicians and allied health professionals, while simultaneously scaling patient engagement tools, stand to accelerate adoption and improve outcomes. Additionally, cross-sector collaboration-spanning pharmaceuticals, device manufacturers, health systems, and technology providers-creates opportunities to deliver end-to-end solutions that address both the biological and behavioral components of obesity, positioning organizations to capture more of the continuum of care.

Practical and coordinated actions for leaders to fortify supply chains, build value-based evidence, and expand integrated patient delivery models to safeguard access and accelerate adoption

Industry leaders should pursue a coordinated set of actions that align clinical evidence generation, supply chain resilience, and payer engagement to preserve access and sustain innovation. First, diversify sourcing and invest in regional manufacturing or strategic supplier partnerships to mitigate exposure to trade policy disruptions and to reduce lead-time risk for critical inputs such as active pharmaceutical ingredients and single-use devices. Complement supply-side measures with inventory optimization and contractual clauses that allow for flexibility during periods of geopolitical uncertainty.

Second, prioritize the generation of rigorous real-world evidence and health economic models that demonstrate long-term value across relevant patient populations and care settings. Use pragmatic trials, registries, and payer data partnerships to quantify outcomes that matter to payers, including reductions in comorbidity burden, hospital utilization, and total cost of care. Third, innovate in patient support and delivery models: integrate digital therapeutics, remote monitoring, and multidisciplinary care coordination to improve adherence and persistence, while reducing the burden on brick-and-mortar facilities.

Fourth, engage proactively with payers and health technology assessment bodies to design reimbursement pathways that reflect longitudinal benefits rather than short-term cost metrics. Consider pilots for outcomes-based contracts that align pricing to sustained clinical endpoints. Fifth, tailor regional market entry and commercialization strategies to local regulatory requirements, cultural contexts, and infrastructure realities, using local partnerships to expedite uptake. Finally, invest in workforce development by equipping clinicians, nurses, and allied health professionals with the training and tools needed to deliver complex chronic-disease management effectively. Together, these actions will strengthen organizational resilience and help sustain patient access during periods of disruption.

A layered research methodology blending primary stakeholder interviews, targeted secondary intelligence, and rigorous triangulation to ensure actionable and defensible insights

The research approach combines a layered methodology designed to triangulate insights from diverse and credible sources. The primary research component includes structured interviews with clinicians, payers, procurement leaders, and patient advocacy representatives to capture firsthand perspectives on clinical decision-making, reimbursement constraints, and access barriers. Supplementing these interviews, expert advisory panels provide thematic validation and scenario testing to stress-test strategic assumptions and to surface emerging operational risks.

Secondary research draws on peer-reviewed clinical literature, regulatory filings, public policy documents, and published guidance from relevant health authorities to construct the clinical and regulatory context. Commercial intelligence is gathered from company disclosures, trial registries, and patent landscapes to map competitive positioning and innovation trajectories. Where appropriate, real-world datasets and claims analyses are used to assess utilization patterns and care pathways, while methodological safeguards-such as data cleaning, outlier analysis, and triangulation-ensure analytical rigor.

Analytical techniques include thematic synthesis for qualitative inputs, comparative regulatory analysis, and health economic modeling frameworks to interpret cost and outcome relationships qualitatively. Limitations of the methodology are acknowledged: stakeholder perspectives may evolve rapidly with new clinical data or policy changes, and access to certain proprietary datasets can constrain granularity. To mitigate these limitations, iterative updates and targeted follow-up interviews are recommended following major regulatory or clinical developments.

A concise synthesis emphasizing the strategic imperative to combine clinical evidence, operational resilience, and payer engagement to enhance outcomes and sustain access

The obesity treatment ecosystem is at an inflection point where clinical innovation, supply chain realities, and payer expectations converge to redefine care pathways. Stakeholders that proactively align evidence generation with pragmatic access strategies and resilient operational planning will capture disproportionate value while improving patient outcomes. The interplay between pharmacologic advances and procedural care underscores the need for integrated, multidisciplinary approaches that account for patient heterogeneity and long-term management needs.

Managing near-term risks-such as trade policy shifts, supply chain constraints, and reimbursement variability-requires deliberate actions that include sourcing diversification, targeted real-world evidence development, and close payer collaboration. Simultaneously, investments in digital care models and patient support mechanisms can enhance adherence and extend the benefits of clinical advances to broader patient populations. In sum, the path forward favors organizations that balance scientific rigor with operational agility and who partner across the care continuum to deliver measurable, sustainable improvements in patient health.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Obesity Treatment Market, by Treatment Type

  • 8.1. Pharmacotherapy
    • 8.1.1. Over-The-Counter Drugs
    • 8.1.2. Prescription Medications
  • 8.2. Surgical Procedures
    • 8.2.1. Bariatric Surgery
    • 8.2.2. Gastric Bypass
    • 8.2.3. Laparoscopic Surgery

9. Obesity Treatment Market, by Drug Class

  • 9.1. Appetite Suppressants
  • 9.2. GLP-1 Receptor Agonists
  • 9.3. Lipase Inhibitors
  • 9.4. Metabolism Boosters

10. Obesity Treatment Market, by Route of Administration

  • 10.1. Oral
  • 10.2. Parenteral

11. Obesity Treatment Market, by Patient Age Group

  • 11.1. Adults
  • 11.2. Elderly
  • 11.3. Pediatric

12. Obesity Treatment Market, by Distribution Channel

  • 12.1. Offline Retail
  • 12.2. Online Retail

13. Obesity Treatment Market, by End-User

  • 13.1. Hospitals & Clinics
  • 13.2. Specialty Clinics
  • 13.3. Weight Loss & Wellness Centers

14. Obesity Treatment Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Obesity Treatment Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Obesity Treatment Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Obesity Treatment Market

18. China Obesity Treatment Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. Apollo Endosurgery, Inc.
  • 19.7. AstraZeneca PLC
  • 19.8. Atkins Nutritionals, Inc.
  • 19.9. BTL Aesthetics
  • 19.10. C.H. Boehringer Sohn AG & Ko. KG
  • 19.11. Eli Lilly and Company
  • 19.12. F. Hoffmann-La Roche Ltd
  • 19.13. GlaxoSmithKline plc.
  • 19.14. Herbalife Ltd.
  • 19.15. Johnson & Johnson Services, Inc.
  • 19.16. Kellogg Company
  • 19.17. Medtronic PLC
  • 19.18. Merck & Co.
  • 19.19. Novo Nordisk A/S
  • 19.20. NutriSystem, Inc.
  • 19.21. Olympus Corporation
  • 19.22. Pfizer, Inc.
  • 19.23. ReShape Lifesciences, Inc.
  • 19.24. Rhythm Pharmaceuticals, Inc.
  • 19.25. Sanofi SA
  • 19.26. Takeda Pharmaceutical Company Limited
  • 19.27. Viking Therapeutics, Inc.
  • 19.28. VIVUS LLC
  • 19.29. Zealand Pharma A/S

LIST OF FIGURES

  • FIGURE 1. GLOBAL OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL OBESITY TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL OBESITY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL OBESITY TREATMENT MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL OBESITY TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL OBESITY TREATMENT MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL OBESITY TREATMENT MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL OBESITY TREATMENT MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PRESCRIPTION MEDICATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PRESCRIPTION MEDICATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PRESCRIPTION MEDICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL OBESITY TREATMENT MARKET SIZE, BY BARIATRIC SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL OBESITY TREATMENT MARKET SIZE, BY BARIATRIC SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL OBESITY TREATMENT MARKET SIZE, BY BARIATRIC SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GASTRIC BYPASS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GASTRIC BYPASS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GASTRIC BYPASS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL OBESITY TREATMENT MARKET SIZE, BY LAPAROSCOPIC SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL OBESITY TREATMENT MARKET SIZE, BY LAPAROSCOPIC SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL OBESITY TREATMENT MARKET SIZE, BY LAPAROSCOPIC SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL OBESITY TREATMENT MARKET SIZE, BY APPETITE SUPPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL OBESITY TREATMENT MARKET SIZE, BY APPETITE SUPPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL OBESITY TREATMENT MARKET SIZE, BY APPETITE SUPPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL OBESITY TREATMENT MARKET SIZE, BY LIPASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL OBESITY TREATMENT MARKET SIZE, BY LIPASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL OBESITY TREATMENT MARKET SIZE, BY LIPASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL OBESITY TREATMENT MARKET SIZE, BY METABOLISM BOOSTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL OBESITY TREATMENT MARKET SIZE, BY METABOLISM BOOSTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL OBESITY TREATMENT MARKET SIZE, BY METABOLISM BOOSTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ELDERLY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ELDERLY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ELDERLY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL OBESITY TREATMENT MARKET SIZE, BY OFFLINE RETAIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL OBESITY TREATMENT MARKET SIZE, BY OFFLINE RETAIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL OBESITY TREATMENT MARKET SIZE, BY OFFLINE RETAIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ONLINE RETAIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ONLINE RETAIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL OBESITY TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL OBESITY TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL OBESITY TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL OBESITY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL OBESITY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL OBESITY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL OBESITY TREATMENT MARKET SIZE, BY WEIGHT LOSS & WELLNESS CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL OBESITY TREATMENT MARKET SIZE, BY WEIGHT LOSS & WELLNESS CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL OBESITY TREATMENT MARKET SIZE, BY WEIGHT LOSS & WELLNESS CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL OBESITY TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS OBESITY TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 156. GCC OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GCC OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. GCC OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 159. GCC OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 160. GCC OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 161. GCC OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 162. GCC OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. GCC OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. GCC OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 183. G7 OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. G7 OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. G7 OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 186. G7 OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 187. G7 OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 188. G7 OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 189. G7 OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 190. G7 OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. G7 OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 192. NATO OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. NATO OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. NATO OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 195. NATO OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 196. NATO OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 197. NATO OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 198. NATO OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 199. NATO OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. NATO OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)